Mercator MedSystems, Inc.   Report issue

For profit Phase 2 Phase 3 Phase 4
Founded: San Leandro CA United States (2000)
Status: No NME R&D (2000)

Organization Overview

First Clinical Trial
2013
NCT01983449
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Mercator MedSystems, Inc.

Active Ingredients

Drugs in Phase 4 Trials (1)

urea (3 trials)

Drugs in Phase 3 Trials (1)

temsirolimus (torisel) (3 trials)

Drugs in Phase 2 Trials (2)

dexamethasone (3 trials)

sodium chloride (1 trial)

Drugs in Other Trials (1)

paclitaxel (taxol) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Ischemia (Phase 3)

Peripheral Arterial Disease (Phase 4)

Peripheral Vascular Diseases (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 9
  • # of Trial APIs: 5